Literature DB >> 27668701

Bacterial fatty acid metabolism in modern antibiotic discovery.

Jiangwei Yao1, Charles O Rock2.   

Abstract

Bacterial fatty acid synthesis is essential for many pathogens and different from the mammalian counterpart. These features make bacterial fatty acid synthesis a desirable target for antibiotic discovery. The structural divergence of the conserved enzymes and the presence of different isozymes catalyzing the same reactions in the pathway make bacterial fatty acid synthesis a narrow spectrum target rather than the traditional broad spectrum target. Furthermore, bacterial fatty acid synthesis inhibitors are single-targeting, rather than multi-targeting like traditional monotherapeutic, broad-spectrum antibiotics. The single-targeting nature of bacterial fatty acid synthesis inhibitors makes overcoming fast-developing, target-based resistance a necessary consideration for antibiotic development. Target-based resistance can be overcome through multi-targeting inhibitors, a cocktail of single-targeting inhibitors, or by making the single targeting inhibitor sufficiently high affinity through a pathogen selective approach such that target-based mutants are still susceptible to therapeutic concentrations of drug. Many of the pathogens requiring new antibiotic treatment options encode for essential bacterial fatty acid synthesis enzymes. This review will evaluate the most promising targets in bacterial fatty acid metabolism for antibiotic therapeutics development and review the potential and challenges in advancing each of these targets to the clinic and circumventing target-based resistance. This article is part of a Special Issue entitled: Bacterial Lipids edited by Russell E. Bishop.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibiotic discovery; Bacterial fatty acid synthesis; Resistance

Mesh:

Substances:

Year:  2016        PMID: 27668701      PMCID: PMC5364071          DOI: 10.1016/j.bbalip.2016.09.014

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Cell Biol Lipids        ISSN: 1388-1981            Impact factor:   4.698


  126 in total

1.  The kalimantacin/batumin biosynthesis operon encodes a self-resistance isoform of the FabI bacterial target.

Authors:  Wesley Mattheus; Joleen Masschelein; Ling-Jie Gao; Piet Herdewijn; Bart Landuyt; Guido Volckaert; Rob Lavigne
Journal:  Chem Biol       Date:  2010-10-29

2.  Viability of a capsule- and lipopolysaccharide-deficient mutant of Neisseria meningitidis.

Authors:  Martine P Bos; Jan Tommassen
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea.

Authors:  Jong Hwa Yum; Chang Ki Kim; Dongeun Yong; Kyungwon Lee; Yunsop Chong; Cheol Min Kim; Jeong Mi Kim; Seonggu Ro; Joong Myung Cho
Journal:  Antimicrob Agents Chemother       Date:  2007-04-09       Impact factor: 5.191

4.  From multidrug-resistant to extensively drug-resistant tuberculosis in Lisbon, Portugal: the stepwise mode of resistance acquisition.

Authors:  João Perdigão; Rita Macedo; Carla Silva; Diana Machado; Isabel Couto; Miguel Viveiros; Luisa Jordao; Isabel Portugal
Journal:  J Antimicrob Chemother       Date:  2012-10-10       Impact factor: 5.790

5.  The 1.8 A crystal structure and active-site architecture of beta-ketoacyl-acyl carrier protein synthase III (FabH) from escherichia coli.

Authors:  C Davies; R J Heath; S W White; C O Rock
Journal:  Structure       Date:  2000-02-15       Impact factor: 5.006

6.  A missense mutation in the fabB (beta-ketoacyl-acyl carrier protein synthase I) gene confers tiolactomycin resistance to Escherichia coli.

Authors:  Suzanne Jackowski; Yong-Mei Zhang; Allen C Price; Stephen W White; Charles O Rock
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

7.  Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.

Authors:  Jun Wang; Srinivas Kodali; Sang Ho Lee; Andrew Galgoci; Ronald Painter; Karen Dorso; Fred Racine; Mary Motyl; Lorraine Hernandez; Elizabeth Tinney; Steven L Colletti; Kithsiri Herath; Richard Cummings; Oscar Salazar; Ignacio González; Angela Basilio; Francisca Vicente; Olga Genilloud; Fernando Pelaez; Hiranthi Jayasuriya; Katherine Young; Doris F Cully; Sheo B Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-24       Impact factor: 11.205

Review 8.  Phosphatidic acid synthesis in bacteria.

Authors:  Jiangwei Yao; Charles O Rock
Journal:  Biochim Biophys Acta       Date:  2012-08-30

Review 9.  Paul Ehrlich's magic bullet concept: 100 years of progress.

Authors:  Klaus Strebhardt; Axel Ullrich
Journal:  Nat Rev Cancer       Date:  2008-05-12       Impact factor: 60.716

10.  Novel acyl phosphate mimics that target PlsY, an essential acyltransferase in gram-positive bacteria.

Authors:  Kimberly D Grimes; Ying-Jie Lu; Yong-Mei Zhang; Vicki A Luna; Julian G Hurdle; Elizabeth I Carson; Jianjun Qi; Sucheta Kudrimoti; Charles O Rock; Richard E Lee
Journal:  ChemMedChem       Date:  2008-12       Impact factor: 3.466

View more
  26 in total

1.  Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.

Authors:  Youchao Deng; Xiang Weng; Yuling Li; Meng Su; Zhongqing Wen; Xinxin Ji; Nan Ren; Ben Shen; Yanwen Duan; Yong Huang
Journal:  J Med Chem       Date:  2019-07-02       Impact factor: 7.446

2.  Pimelic acid, the first precursor of the Bacillus subtilis biotin synthesis pathway, exists as the free acid and is assembled by fatty acid synthesis.

Authors:  Miglena Manandhar; John E Cronan
Journal:  Mol Microbiol       Date:  2017-03-03       Impact factor: 3.501

Review 3.  Exogenous fatty acid metabolism in bacteria.

Authors:  Jiangwei Yao; Charles O Rock
Journal:  Biochimie       Date:  2017-06-28       Impact factor: 4.079

Review 4.  Structural approaches to pathway-specific antimicrobial agents.

Authors:  Michael E Johnson; Leslie W-M Fung
Journal:  Transl Res       Date:  2020-02-06       Impact factor: 7.012

5.  Semisynthesis of Platensimycin Derivatives with Antibiotic Activities in Mice via Suzuki-Miyaura Cross-Coupling Reactions.

Authors:  Youchao Deng; Meng Su; Dingding Kang; Xingyun Liu; Zhongqing Wen; Yuling Li; Lin Qiu; Ben Shen; Yanwen Duan; Yong Huang
Journal:  J Med Chem       Date:  2018-12-05       Impact factor: 7.446

6.  The genome of a Bacteroidetes inhabitant of the human gut encodes a structurally distinct enoyl-acyl carrier protein reductase (FabI).

Authors:  Christopher D Radka; Matthew W Frank; Jiangwei Yao; Jayaraman Seetharaman; Darcie J Miller; Charles O Rock
Journal:  J Biol Chem       Date:  2020-04-21       Impact factor: 5.157

Review 7.  Overview of the Cellular Stress Responses Involved in Fatty Acid Overproduction in E. coli.

Authors:  Neha Sawant; Harinder Singh; Deepti Appukuttan
Journal:  Mol Biotechnol       Date:  2021-11-18       Impact factor: 2.695

8.  Exploring the chemical space of 1,2,3-triazolyl triclosan analogs for discovery of new antileishmanial chemotherapeutic agents.

Authors:  Julia Fernández de Luco; Alejandro I Recio-Balsells; Diego G Ghiano; Ana Bortolotti; Juán Manuel Belardinelli; Nina Liu; Pascal Hoffmann; Christian Lherbet; Peter J Tonge; Babu Tekwani; Héctor R Morbidoni; Guillermo R Labadie
Journal:  RSC Med Chem       Date:  2020-11-05

Review 9.  Novel Targets for Antimicrobials.

Authors:  Suchita Gupta; Vaishali Ravindra Undale; Kedar Lakhadive
Journal:  Turk J Pharm Sci       Date:  2020-10-30

10.  Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.

Authors:  Yuling Li; Xiang Weng; Youchao Deng; Jian Pan; Saibin Zhu; Zhongqing Wen; Yanqiu Yuan; Shaowen Li; Ben Shen; Yanwen Duan; Yong Huang
Journal:  ACS Med Chem Lett       Date:  2021-02-15       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.